UCLA 'Armored' CAR-T Cells Show Preclinical Gains Against Glioblastoma and Ovarian Cancer

Overview

• In mouse studies published in Science Translational Medicine, VEGF-blocking CAR-T cells outperformed standard CAR-Ts and CAR-T plus systemic anti-VEGF, cutting tumor growth and extending survival.
• In multiple aggressive glioma models, complete responses reached 63–88% with the armored cells compared with 0–38% using conventional CAR-T therapy.
• The approach prevented the abnormal blood vessel growth and hypoxia seen after conventional CAR-T treatment in glioma models.
• In ovarian cancer models, including a recurrent patient-derived tumor, the therapy slowed progression, prolonged survival, and increased interferon-gamma levels.
• The VEGF-targeting scFv was developed with Academia Sinica, and investigators emphasize the results are preclinical and require further validation before human trials.